Now showing items 1-2 of 2

    • Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study 

      Cunningham, Evan B; Hajarizadeh, Behzad; Dalgard, Olav; Amin, Janaki; Hellard, Margaret; Foster, Graham R; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Marks, Philippa S; Quiene, Sophie; Applegate, Tanya L; Weltman, Martin; Shaw, David; Dunlop, Adrian; Bruneau, Julie; Midgard, Håvard; Bourgeois, Stefan; Thurnheer, Maria Christine; Dore, Gregory J; Grebely, Jason; Shaw, Ineke; Siriragavan, Sharmila; Horschik, Tina; Sharma, Shawn; Eevers, Anita; Andreassen, Jessica; Melkeraaen, Ingunn; Widder, Nicole; Lesneuck, Kristof; Kotsoros, Barbara; Hazelwood, Susan; Holland, Rohan; Axten, David; Von Bibra, Sally; Powis, Jeff; Mason, Kate; Ryder, Stephen; Jack, Kate; Scheidegger, Claude; Huber, Christine; Ferguson, Catherine; Staehelin, Cornelia; Lacalamita, Melanie; Fragomeli, Vincenzo; Sevehon, Alison (BMC Springer, 2017-06-13)
      Background The aims of this analysis were to investigate treatment completion and adherence among people with ongoing injecting drug use or receiving opioid substitution therapy (OST) in a study of response-guided therapy ...
    • Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study 

      Grebely, Jason; Dalgard, Olav; Cunningham, Evan B; Hajarizadeh, Behzad; Foster, Graham R; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Amin, Janaki; Marks, Philippa S; Quiene, Sophie; Applegate, Tanya L; Weltman, Martin; Shaw, David; Dunlop, Adrian; Hellard, Margaret; Bruneau, Julie; Midgard, Håvard; Bourgeois, Stefan; Staehelin, Cornelia; Dore, Gregory J (Elsevier, 2017-09)
      Background There are few data on treatment for hepatitis C virus (HCV) infection among people with ongoing injecting drug use. This study evaluated the efficacy of response-guided therapy for chronic HCV genotypes 2/3 ...